The DxC 500i Clinical Analyzer is a new integrated clinical chemistry and immunoassay platform capable of automating 170+ preprogrammed assays across diverse sample types. A comprehensive evaluation at Tata Medical Center assessed the analyzer's performance on 31 critical analytes essential for metabolic management of cancer patients. The study followed rigorous CLSI EP15-A3 guidelines, comparing precision and method correlation against the established Vitros XT 7600 platform to validate analytical reliability in tertiary cancer care settings.

Key Study Findings:

• Exceptional precision performance: The DxC 500i analyzer demonstrated total imprecision figures lower than European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recommendations across multiple specification levels
• Outstanding comparative accuracy: When compared to the established Vitros XT 7600 platform, 12 of 16 analytes showed Pearson's correlation coefficients of 0.99, with the remaining four above 0.96
• Comprehensive analyte validation: All 31 tested analytes passed manufacturer's precision claims, with 96% of analytes meeting EFLM minimal specification limits
• Clinical readiness confirmed: The analyzer demonstrated suitability for regular use in tertiary oncology clinics and small-to-medium laboratories, with excellent accuracy facilitating reliable result interpretation

Read the full study to discover how the DxC 500i Clinical Analyzer delivers superior precision for cancer patient care. Download study